Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 101

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 7
Chunk 101
---
ized approximately $55 million cash dividend payment on the MCPS.

On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock in 2024 or 2023, and had the full amount available under the authorization as of December 31, 2024. There were approximately 263 million shares in treasury as of December 31, 2024 and 2023.

49

Contractual Obligations and Commitments

(in millions)20252026202720282029ThereafterTotalDebt obligations(1)$1,730 $255 $935 $1,123 $1,051 $5,547 $10,642 Interest payments(2)288 270 266 253 234 1,385 2,695 Lease obligations(3)94 84 64 52 43 227 564 Purchase obligations(2)881 220 125 108 21 159 1,514 Legal reserves(4)177 — — — — — 177 One-time transition tax147 — — — — — 147 $3,316 $829 $1,390 $1,536 $1,349 $7,318 $15,739 

(1)Debt obligations are comprised of our senior notes outstanding as of December 31, 2024. This does not include unamortized debt issuance 

discounts, deferred financing costs and gains on fair value hedges or finance lease obligations. Refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information.

(2)In accordance with U.S. GAAP, these obligations relate primarily to expenses associated with future periods and, with the exception of accrued interest, are not reflected in our consolidated balance sheet as of December 31, 2024. Interest payments included above are calculated based on rates and required fees applicable to our outstanding debt obligations as of December 31, 2024 described in Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form